Predictors of long-term progression-free survival in ovarian cancer patients treated with niraparib
Key Findings
In a study on advanced ovarian cancer patients receiving niraparib maintenance therapy, certain factors were found to be associated with long-term progression-free survival (≥2 years).
Practical Implications
The study identified that patients with BRCA1/2 mutation/homologous recombination-deficiency status, FIGO stage III, and fewer baseline non-target lesions were more likely to achieve long-term progression-free survival.
Value in Clinical Practice
Understanding these predictors can help clinicians in making treatment decisions and providing personalized care to patients with advanced ovarian cancer.
About the Study
This post hoc analysis of the PRIMA trial involved 487 patients and utilized logistic regression modeling to identify predictive factors for long-term progression-free survival.
